

# Chemical modification of auranofin yields a new family of anticancer drug candidates: the gold(I) Phosphite analogues

Damiano Cirri, Andrea Geri, Lara Massai, Michele Mannelli, Tania Gamberi, Chiara Gabbiani, Francesca Magherini, Matteo Becatti, Alessandro Pratesi and Luigi Messori




Figure S1: <sup>31</sup>P NMR spectrum performed at *t*<sub>0</sub> on AuP(OCH<sub>3</sub>)<sub>3</sub>Cl. Solvent: MeOD-d<sub>4</sub>/H<sub>2</sub>O 1:1




Figure S2: <sup>31</sup>P NMR spectrum performed at 72h on AuP(OCH<sub>3</sub>)<sub>3</sub>Cl. Solvent: MeOD-d<sub>4</sub>/H<sub>2</sub>O 1:1




Figure S3: <sup>31</sup>P NMR spectrum performed at  $t_0$  on  $\text{AuP}(\text{OCH}_3)_3\text{Br}$ . Solvent:  $\text{MeOD-d}_4/\text{H}_2\text{O}$  1:1




Figure S4: <sup>31</sup>P NMR spectrum performed at 72h on  $\text{AuP}(\text{OCH}_3)_3\text{Br}$ . Solvent:  $\text{MeOD-d}_4/\text{H}_2\text{O}$  1:1




Figure S5:  $^{31}\text{P}$ NMR spectrum performed at  $t_0$  on  $\text{AuP}(\text{OCH}_3)_3\text{I}$ . Solvent:  $\text{MeOD-d}_4/\text{H}_2\text{O}$  1:1




Figure S6:  $^{31}\text{P}$ NMR spectrum performed at 72h on  $\text{AuP}(\text{OCH}_3)_3\text{I}$ . Solvent:  $\text{MeOD-d}_4/\text{H}_2\text{O}$  1:1




Figure S7:  $^{31}\text{P}$ NMR spectrum performed at  $t_0$  on  $\text{AuP}(\text{OCH}_3)_3\text{STga}$ . Solvent:  $\text{MeOD-d}_4/\text{H}_2\text{O}$  1:1




Figure S8:  $^{31}\text{P}$ NMR spectrum performed at 72h on  $\text{AuP}(\text{OCH}_3)_3\text{STga}$ . Solvent:  $\text{MeOD-d}_4/\text{H}_2\text{O}$  1:1




Figure S9: Cell Viability Assay. MTT time course assay at 24, 48, and 72 h of drug exposure by using their 72-h exposure IC50 doses.